erythromycin ethylsuccinate; sulfisoxazole acetyl
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL (erythromycin ethylsuccinate; sulfisoxazole acetyl) by Teva is clinical pharmacology: orally administered erythromycin ethylsuccinate suspensions are readily and reliably absorbed. Approved for the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1988.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY: Orally administered erythromycin ethylsuccinate suspensions are readily and reliably absorbed. Erythromycin ethylsuccinate products have demonstrated rapid and consistent absorption in both fasting and nonfasting conditions. However, higher serum concentrations are obtained…
Worked on ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.